RARE – Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.

RARE

$35.69

Name : Ultragenyx Pharmaceutical Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,351,280,128.00

EPSttm : -6.29

Ultragenyx Pharmaceutical Inc.

$35.69

2.03%

$0.71

Float Short %

5.17

Margin Of Safety %

Put/Call OI Ratio

0.71

EPS Next Q Diff

0.03

EPS Last/This Y

0.93

EPS This/Next Y

1.9

Price

35.69

Target Price

91.8

Analyst Recom

1.2

Performance Q

-12.63

Relative Volume

0.85

Beta

0.35

Ticker: RARE

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-20	RARE	38.85	0.97	0.03	23062
2025-03-21	RARE	39.15	0.94	0.00	23479
2025-03-24	RARE	39.35	0.96	16.00	23032
2025-03-25	RARE	38.72	0.97	0.25	23049
2025-03-26	RARE	38	0.97	0.24	23054
2025-03-27	RARE	38.91	0.93	0.77	23717
2025-03-28	RARE	37.78	0.93	0.02	23735
2025-03-31	RARE	36.24	0.92	1.07	23836
2025-04-01	RARE	33.96	0.93	0.01	23846
2025-04-02	RARE	35.36	0.82	0.06	25092
2025-04-03	RARE	35.13	0.75	0.15	26379
2025-04-04	RARE	32.46	0.75	1.82	26386
2025-04-07	RARE	32.14	0.75	0.63	26395
2025-04-08	RARE	31.08	0.75	1.29	26397
2025-04-09	RARE	33.95	0.75	0.50	26594
2025-04-10	RARE	33.22	0.75	1.02	26597
2025-04-11	RARE	34.12	0.74	0.00	26382
2025-04-14	RARE	34.86	0.74	1.00	26380
2025-04-15	RARE	35.36	0.74	0.80	26386
2025-04-16	RARE	35	0.75	0.00	26871
2025-04-17	RARE	35.63	0.71	0.96	26277
2025-04-18	RARE	35.69	0.71	0.83	26277
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-20	RARE	38.89	20.1	-	-5.43
2025-03-21	RARE	39.15	20.1	-	-5.43
2025-03-24	RARE	39.36	20.1	-	-5.43
2025-03-25	RARE	38.69	20.1	-	-5.43
2025-03-26	RARE	37.98	20.1	-	-5.43
2025-03-27	RARE	38.91	20.1	-	-5.43
2025-03-28	RARE	37.82	20.1	-	-5.43
2025-03-31	RARE	36.21	20.2	-	-5.36
2025-04-01	RARE	33.84	20.2	-	-5.36
2025-04-02	RARE	35.37	20.2	-	-5.36
2025-04-03	RARE	35.13	20.2	-	-5.36
2025-04-04	RARE	32.44	20.2	-	-5.36
2025-04-07	RARE	32.17	19.1	-	-5.36
2025-04-08	RARE	31.06	19.1	-	-5.36
2025-04-09	RARE	33.91	19.1	-	-5.36
2025-04-10	RARE	33.15	19.1	-	-5.36
2025-04-11	RARE	34.11	19.1	-	-5.36
2025-04-14	RARE	34.92	19.1	-	-5.36
2025-04-15	RARE	35.34	19.1	-	-5.36
2025-04-16	RARE	35.01	19.1	-	-5.36
2025-04-17	RARE	35.69	19.1	-	-5.36
2025-04-18	RARE	35.69	19.1	-	-5.36
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-20	RARE	-2.94	0.43	5.32
2025-03-21	RARE	-2.94	0.43	5.32
2025-03-24	RARE	-2.94	0.41	5.32
2025-03-25	RARE	-2.94	0.41	5.32
2025-03-26	RARE	-2.94	0.41	5.58
2025-03-27	RARE	-2.94	0.41	5.58
2025-03-28	RARE	-2.94	0.41	5.58
2025-03-31	RARE	-2.94	0.40	5.58
2025-04-01	RARE	-2.94	0.40	5.58
2025-04-02	RARE	-2.94	0.40	5.58
2025-04-03	RARE	-2.94	0.40	5.58
2025-04-04	RARE	-2.94	0.40	5.58
2025-04-07	RARE	-2.90	0.61	5.50
2025-04-08	RARE	-2.90	0.61	5.50
2025-04-09	RARE	-2.90	0.61	5.50
2025-04-10	RARE	-2.90	0.61	5.17
2025-04-11	RARE	-2.90	0.61	5.17
2025-04-14	RARE	-2.78	0.64	5.17
2025-04-15	RARE	-2.78	0.64	5.17
2025-04-16	RARE	-2.78	0.64	5.17
2025-04-17	RARE	-2.78	0.64	5.17
2025-04-18	RARE	-2.78	0.64	5.17
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-1.39

Avg. EPS Est. Current Quarter

-1.62

Avg. EPS Est. Next Quarter

-1.36

Insider Transactions

-2.78

Institutional Transactions

0.64

Beta

0.35

Average Sales Estimate Current Quarter

145

Average Sales Estimate Next Quarter

162

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

80.1

Max Drawdown 5-Year %

-82.5

Target Price

91.8

P/E

Forward P/E

PEG

P/S

5.98

P/B

12.92

P/Free Cash Flow

EPS

-6.34

Average EPS Est. Cur. Y

-5.36

EPS Next Y. (Est.)

-3.46

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-101.6

Relative Volume

0.85

Return on Equity vs Sector %

-242.9

Return on Equity vs Industry %

-229.5

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.02

EBIT Estimation

Ultragenyx Pharmaceutical Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 1294

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today

news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance

stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market

stock prices RARE premarket after hours

ticker RARE fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

RARE – Ultragenyx Pharmaceutical Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: RARE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y